Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71836 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Zhinan Ye und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Taizhou Municipal Hospital (Taizhou University Affiliated Municipal Hospital), School of Medicine, Taizhou University, Taizh…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, tau Proteins, Memory Disorders, Complement C3. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
INTRODUCTION The role of complement in Alzheimer's disease (AD) remains unclear, particularly regarding tau pathology and memory decline. METHODS In 123 mild cognitive impairment (MCI) participants from Alzheimer's Disease Neuroimaging Initiative (ADNI), linear mixed‑effects models and Johnson–Neyman analysis examined associations of baseline cerebrospinal fluid (CSF) C3/FH ratio with longitudinal memory decline moderated by time‑varying plasma phosphorylated tau181 (p‑tau181). RESULTS The three‑way interaction was significant ( p = 0.023). A region of statistical significance was identified: the conditional association of C3/FH with memory decline became significant when p‑tau181 exceeded 0.76 SD, with higher C3/FH associated with slower decline at elevated p‑tau181 levels. Cross‐sectionally, no significant C3/FH–memory associations were observed in any diagnostic group (all p > 0.05). DISCUSSION These findings indicate that complement balance is associated with memory decline in MCI in a manner dependent on plasma p‑tau181 levels, suggesting that complement may interact with AD‑related pathophysiology during the prodromal phase. The identified statistical region provides a hypothesis‑generating benchmark for future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Taizhou Municipal Hospital (Taizhou University Affiliated Municipal Hospital), School of Medicine, Taizhou University, Taizhou, Zhejiang, China.
- Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
- The First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- The School of Mental Health, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
- Renji College, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Förderung
- NIA NIH HHS
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Ye, Z., Zhang, Q., Zhang, B., Teng, B., Wang, S., Chen, J., Li, B., Jin, H., Zheng, Z., Yang, Z., Hu, X., Zhao, X., Huang, S., Weng, Y., & Yang, D. (2026). Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71836
Vancouver
Ye Z, Zhang Q, Zhang B, Teng B, Wang S, Chen J, et al. Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71836
BibTeX
@article{Ye2026,
author = {Ye, Zhinan and Zhang, Qihan and Zhang, Bo and Teng, Bingxin and Wang, Shiyue and Chen, Jiaxuan and Li, Bohao and Jin, Hongjie and Zheng, Zhexin and Yang, Zhuoyu and Hu, Xuanang and Zhao, Xinyan and Huang, Suwen and Weng, Yiyun and Yang, Dehao},
title = {Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71836}
}
EUVIMED